Flaharty Asset Management, LLC Revance Therapeutics, Inc. Transaction History

Flaharty Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$4.65 - $9.31 $148,800 - $297,920	32,000 New	32,000 $157,000
Q1 2023 May 10, 2023	SELL	$18.36 - $35.27 $119,340 - $229,255	-6,500 Reduced 48.32%	6,952 $223,000
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $18,320 - $30,660	1,000 Added 8.03%	13,452 $248,000
Q3 2022 Nov 02, 2022	SELL	$14.33 - $28.47 $71,650 - $142,350	-5,000 Reduced 28.65%	12,452 $336,000
Q2 2022 Jul 11, 2022	BUY	$11.52 - $20.4 $23,040 - $40,800	2,000 Added 12.94%	17,452 $241,000
Q4 2021 Feb 15, 2022	BUY	$12.46 - $27.87 $192,531 - $430,647	15,452 New	15,452 $252,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Flaharty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Flaharty Asset Management, LLC with notifications on news.